Different expression of HMGA1 in hepatocarcinoma and intrahepatic cholangiocarcinoma and its significance

doi:10.3877/cma.j.issn.1647-0793.2013.02.003

Abstract

Abstract:

Objective

To investigate the expression of HMGA1 in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma(IHC) and its significance.

Methods

Immunohistochemistry (SABC method) was applied to detect HMGA1 expression in 60 HCC, 42 IHC, and 10 normal hepatic tissues. The relationship between HMGA1 expresssion and clinicpathological features of HCC and IHC was determined.

Results

No significant nuclear immunoreactivity was found in normal hepatic tissues, while 3.3% (2/60) of HCC, 66.7% (28/42) of IHC showed positive immunoreactivity, and there was significant difference between HCC and IHC(P = 0.000). The expression level of HMGA1 was strongly correlated with the expression level of p53 (r = 0.673, P < 0.05). The expression of HMGA1 in patients who died in one year (80.0%) was higher than that of patients lived(33.3%), and the difference was significant(P < 0.05).

Conclusions

HMGA1 protein level may serve as a potential diagnostic marker that differentiate HCC from IHC. HMGA1 may play an important role in the development of IHC. The high expression level of HMGA1 in IHC is strongly correlated with bad prognosis.

Key words: High mobility group proteins, Hepatocellular, Carcinoma, Intrahepatic cholangiocarcinoma, Immunohistochemistry

Yuan-long YU, Shi-hai ZHOU, Hong CHEN, Ze-min HU, Hui-zhou DENG. Different expression of HMGA1 in hepatocarcinoma and intrahepatic cholangiocarcinoma and its significance[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(02): 91-95.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1647-0793.2013.02.003

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I02/91

Figures/Tables 7

References 19

1	Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem, 1973, 38(1): 14-19.
2	Reeves R, Adair JE. Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair(Amst), 2005, 4(8): 926-938.
3	Hoyos JM, Fedele M, Battista S, et al. Identification of genes up-and down-regulation by the high mobility group A1(HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res, 2004, 64(16): 5728-5735.
4	Fedele M, Battista S, Manfioletti G, et al. Role of the mobility group A proteins in human lipomas. Carcinogenesis, 2001, 22(10): 1583-1591.
5	Thanos M, Maniatis T. Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell, 1995, 83(7): 1091-1100.
6	Masciullo V, Baldassarre G, Pentimalli F, et al. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis, 2003, 24 (7): 1191-1198.
7	Takaha N, Resar LM, Vindivich D, et al. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate, 2004, 60(2): 160-167.
8	Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins1. Cancer Res, 1996, 56(8): 1896-1901.
9	Abe N, Watanabe T, Masaki T, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res, 2000, 60(12): 3117-3122.
10	Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol, 2006, 209(2): 206-212.
11	Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I(Y) HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res, 1998, 58(18): 4193-4198.
12	Chang ZG, Yang LY, Wang W, et al. Determination of high mobility group A1(HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig Dis Sci, 2005, 50(10): 1764-1770.
13	Chuma M, Saeki N, Yamamoto Y, et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med, 2004, 53 (2): 90-97.
14	Abe N, Watanabe T, Izumisato Y, et al. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: Its potential use in the diagnosis of liver neoplasms. J Gastroenterol, 2003, 38(12): 1144-1149.
15	石景森，王炳煌. 胆道外科基础与临床. 北京：人民卫生出版社, 2003: 132-133.
16	Stanley RH, Lauri AA. Pathology and genetics of tumours of the digestive system. World Health Organization, International Agency for Research on Cancer, 2000: 180.
17	Pierantoni GM, Rinaldo C, Esposito F, et al. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ, 2006, 13(9):1554-1563.
18	Esposito F, Tornincasa M, Chieffi P, et al. High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res, 2010, 70(13): 5379-5388.
19	Frasca F, Rustighi A, Malaguarnera R, et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res, 2006, 66(6): 2980-2989.

项目		例数	HMGA1染色（例）		阳性率（%）	χ ²值	P值
项目		例数	-	+ ~+++	阳性率（%）	χ ²值	P值
性别		?	?	?	?	1.750	0.186
?	男	24	6	18	75.0	?	?
?	女	18	8	10	55.6	?	?
年龄（岁）		?	?	?	?	1.000	0.662
?	<60	22	8	14	63.6	?	?
?	≥60	20	6	14	70.0	?	?
肿瘤大小（cm）		?	?	?	?	0.857	0.355
?	<2	14	6	8	57.1	?	?
?	≥2	28	8	20	71.4	?	?
分布位置		?	?	?	?	3.018	0.082
?	左肝	31	8	23	74.2	?	?
?	右肝	11	6	5	45.5	?	?
淋巴结转移		?	?	?	?	1.235	0.266
?	无	34	10	24	70.6	?	?
?	有	8	4	4	50.0	?	?
远处转移		?	?	?	?	1.930	0.165
?	无	34	13	21	61.8	?	?
?	有	8	1	7	87.5	?	?
临床分期		?	?	?	?	3.231	0.072
?	Ⅰ-Ⅱ	16	8	8	50.0	?	?
?	Ⅲ-Ⅳ	26	6	20	76.9	?	?
p53表达		?	?	?	?	10.811	0.001
?	（-）	10	8	2	20.0	?	?
?	（+）	18	3	15	83.3	?	?
伴发结石		?	?	?	?	0.857	0.355
?	无	28	8	20	71.4	?	?
?	有	14	6	8	57.1	?	?
伴有肝吸虫		?	?	?	?	2.211	0.137
?	无	38	14	24	63.2	?	?
?	有	4	0	4	100.0	?	?
CA19-9水平		?	?	?	?	3.231	0.072
?	正常	16	8	8	50.0	?	?
?	升高	26	6	20	76.9	?	?
1年内患者死亡		?	?	?	?	8.400	0.004
?	是	30	6	24	80.0	?	?
?	否	12	8	4	33.3	?	?

项目		例数	HMGA1染色（例）		阳性率（%）	χ ²值	P值
项目		例数	-	+ ~+++	阳性率（%）	χ ²值	P值
性别		?	?	?	?	1.750	0.186
?	男	24	6	18	75.0	?	?
?	女	18	8	10	55.6	?	?
年龄（岁）		?	?	?	?	1.000	0.662
?	<60	22	8	14	63.6	?	?
?	≥60	20	6	14	70.0	?	?
肿瘤大小（cm）		?	?	?	?	0.857	0.355
?	<2	14	6	8	57.1	?	?
?	≥2	28	8	20	71.4	?	?
分布位置		?	?	?	?	3.018	0.082
?	左肝	31	8	23	74.2	?	?
?	右肝	11	6	5	45.5	?	?
淋巴结转移		?	?	?	?	1.235	0.266
?	无	34	10	24	70.6	?	?
?	有	8	4	4	50.0	?	?
远处转移		?	?	?	?	1.930	0.165
?	无	34	13	21	61.8	?	?
?	有	8	1	7	87.5	?	?
临床分期		?	?	?	?	3.231	0.072
?	Ⅰ-Ⅱ	16	8	8	50.0	?	?
?	Ⅲ-Ⅳ	26	6	20	76.9	?	?
p53表达		?	?	?	?	10.811	0.001
?	（-）	10	8	2	20.0	?	?
?	（+）	18	3	15	83.3	?	?
伴发结石		?	?	?	?	0.857	0.355
?	无	28	8	20	71.4	?	?
?	有	14	6	8	57.1	?	?
伴有肝吸虫		?	?	?	?	2.211	0.137
?	无	38	14	24	63.2	?	?
?	有	4	0	4	100.0	?	?
CA19-9水平		?	?	?	?	3.231	0.072
?	正常	16	8	8	50.0	?	?
?	升高	26	6	20	76.9	?	?
1年内患者死亡		?	?	?	?	8.400	0.004
?	是	30	6	24	80.0	?	?
?	否	12	8	4	33.3	?	?

p53表达	例数	HMGA1表达
p53表达	例数	-	+	++	+++
p53(－)	10	8	1	1	0
p53（＋）	11	2	3	5	1
p53（+＋）	7	1	0	2	4

p53表达	例数	HMGA1表达
p53表达	例数	-	+	++	+++
p53(－)	10	8	1	1	0
p53（＋）	11	2	3	5	1
p53（+＋）	7	1	0	2	4

[1]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[2]	Weiping Zhang, Jingling Wang, Zhixing Liu, Li Chen, Fangqun Chen. Characteristics of time-intensity curve of high-frame-rate contrast-enhanced ultrasound in clear cell renal cell carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 916-922.
[3]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[4]	Yaping Jia, Shu'e Zeng. Ultrasound and pathological characteristics of breast metaplastic carcinoma containing squamous cell carcinoma components [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 844-848.
[5]	Guo Sun, Yingdong Xie, Chaoli Xu, Bin Yang. Clinical value of a nomogram based on ultrasonic and clinical features for predicting central and lateral cervical lymph node metastases of thyroid papillary carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(07): 734-742.
[6]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[7]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[8]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[9]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Yu Han, Wu Zhang, Anqi Li, Wenying Chen, Sidong Xie. Diagnostic value of MRI Liver Image Reporting and Data System (LI-RADS) for hepatocellular carcinoma in patients with non-cirrhotic hepatitis B [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 669-673.
[12]	Can Tang, Xiangyang Li, Haoran Qin, Jing Li, Tianyun Wang, Yang Ke, Hong Zhu. Diagnosis, treatment and efficacy analysis of 12 cases of primary hepatic neuroendocrine neoplasm: a single center study [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 674-680.
[13]	Weizhi Zhang, Lianxin Liu. Expression and significance of IPO7 in hepatocellular carcinoma based on bioinformatics analysis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 694-701.
[14]	An Chen, Juan Feng, Zhenyu Yang, Xilin Du, Qiangshan Bai, Jikai Yin, Li Zang, Jianguo Lu. Analysis of CCN4 expression and its clinical significance in hepatocellular carcinoma based on bioinformatics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 702-707.
[15]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.

Please choose a citation manager

Content to export